Pharma Investments, Ventures & Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures & Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
New Alzheimer disease research from H.Y. Zhang et al outlined
May 18th, 2008
According to recent research from Shanghai, People's Republic of China, "The use of acetylcholinesterase inhibitors to decrease the breakdown of the neurotransmitter acetylcholine has been the main symptomatic therapy for mild to moderate Alzheimer's patients, though the etiology of Alzheimer's disease remains unclear and seems to involve multiple factors. Further evidence has indicated that some of these acetylcholinesterase inhibitors also have non-cholinergic functions on the pathogenesis of Alzheimer's disease including the formation and deposition of beta-amyloid." "Huperzine A, a potent and reversible inhibitor of acetylcholinesterase that was initially isolated...
Source: Pharma Investments, Ventures & Law Weekly (2008-05-18)
|
